Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. Campone M, et al. Among authors: clemons m. Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18. Eur J Cancer. 2018. PMID: 30241001 Clinical Trial.
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Clemons M. Freedman O, et al. Among authors: clemons m. Breast Cancer Res Treat. 2009 Nov;118(2):377-83. doi: 10.1007/s10549-009-0452-8. Epub 2009 Jun 24. Breast Cancer Res Treat. 2009. PMID: 19551499
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Ellard SL, et al. Among authors: clemons m. J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687332 Clinical Trial.
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP, Iscoe N, Gelmon K. Clemons M, et al. Breast Cancer Res Treat. 2010 Nov;124(1):177-86. doi: 10.1007/s10549-010-1152-0. Epub 2010 Sep 3. Breast Cancer Res Treat. 2010. PMID: 20814815 Clinical Trial.
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Cleeland CS, et al. Among authors: clemons m. Cancer. 2013 Feb 15;119(4):832-8. doi: 10.1002/cncr.27789. Epub 2012 Sep 5. Cancer. 2013. PMID: 22951813 Free article. Clinical Trial.
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent RA, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN. Clemons MJ, et al. Breast Cancer Res Treat. 2014 Jul;146(1):153-62. doi: 10.1007/s10549-014-3015-6. Epub 2014 Jun 13. Breast Cancer Res Treat. 2014. PMID: 24924416 Clinical Trial.
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Addison CL, Pond GR, Cochrane B, Zhao H, Chia SK, Levine MN, Clemons M. Addison CL, et al. Among authors: clemons m. J Bone Oncol. 2015 Jun 12;4(2):47-53. doi: 10.1016/j.jbo.2015.04.001. eCollection 2015 Jun. J Bone Oncol. 2015. PMID: 26579488 Free PMC article.
409 results